Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4930 | 194100-83-9 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A highly purified recombinant glycoprotein form of human THYROID-STIMULATING HORMONE, produced by recombinant DNA technology comprising two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites, and a beta subunit of 118 residues containing one N-linked glycosylation site. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.
|
| Dose | Unit | Route |
|---|---|---|
| 0.90 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 26, 1953 | FDA | SANOFI AVENTIS US | |
| March 9, 2000 | EMA | SANOFI B.V. |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nausea | 75.96 | 33.55 | 74 | 886 | 1110242 | 89517245 |
| Blood thyroid stimulating hormone decreased | 56.89 | 33.55 | 13 | 947 | 5727 | 90621760 |
| Product administered at inappropriate site | 55.43 | 33.55 | 12 | 948 | 4139 | 90623348 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product administered at inappropriate site | 60.25 | 32.84 | 13 | 949 | 5380 | 110582957 |
| Nausea | 51.71 | 32.84 | 58 | 904 | 1235632 | 109352705 |
| Blood thyroid stimulating hormone decreased | 51.14 | 32.84 | 12 | 950 | 7227 | 110581110 |
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AB01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Thyrotropin |
| ATC | V04CJ01 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for thyreoidea function |
| FDA CS | M0021496 | Thyrotropin |
| FDA EPC | N0000175949 | Thyroid Stimulating Hormone |
| CHEBI has role | CHEBI:24621 | hormone |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50671 | antithyroid drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Serum thyroglobulin level | indication | 391378005 |
| Species | Use | Relation |
|---|---|---|
| Dogs | No Use Class Stated Or Implied | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Dermathycin Injectable | Intervet Inc. | 1 |
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thyrotropin receptor | GPCR | AGONIST | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| D06120 | KEGG_DRUG |
| 4021142 | VUID |
| N0000180238 | NUI |
| 4021142 | VANDF |
| CHEBI:749567 | CHEBI |
| CHEMBL1201533 | ChEMBL_ID |
| 9002-71-5 | SECONDARY_CAS_RN |
| DB00024 | DRUGBANK_ID |
| DB15263 | DRUGBANK_ID |
| 10579 | RXNORM |
| 14103 | MMSL |
| 7866 | MMSL |
| d04377 | MMSL |
| 002112 | NDDF |
| 007686 | NDDF |
| 326013007 | SNOMEDCT_US |
| 407733000 | SNOMEDCT_US |
| 412520006 | SNOMEDCT_US |
| 65428006 | SNOMEDCT_US |
| C2587204 | UMLSCUI |
| D057073 | MESH_DESCRIPTOR_UI |
| CHEMBL1201532 | ChEMBL_ID |
| 7668 | INN_ID |
| AVX3D5A4LM | UNII |
| 679 | INN_ID |
| D013972 | MESH_DESCRIPTOR_UI |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Thyrogen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0030 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.90 mg | INTRAMUSCULAR | BLA | 28 sections |